Capri­cor shares blast­ed as PhII heart study fails; Sanofi to de­stroy un­used fa­cil­i­ty in France

→ Af­ter look­ing over dis­ap­point­ing in­ter­im re­sults from its Phase II study of CAP-1002 for im­prov­ing out­comes for heart at­tack pa­tients, Capri­cor $CAPR is throw­ing in the tow­el and re­fo­cus­ing on Duchenne mus­cu­lar dy­s­tro­phy. The biotech — which de­vel­ops cell ther­a­pies — says it plans to cut staff in or­der to con­serve cash. Its stock was evis­cer­at­ed, drop­ping 59% on the news.

→ Sanofi spent $126 mil­lion build­ing a pi­lot plant at its Mont­pel­li­er R&D cam­pus in France. But while the com­pa­ny fo­cused on a frus­trat­ing ef­fort to re­duce staff in France, it nev­er opened the fa­cil­i­ty. And now it plans to bull­doze it, cit­ing a chang­ing port­fo­lio, ac­cord­ing to a re­port by in-Phar­ma Tech­nol­o­gist.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER